Nasus Pharma Advances NS002 Clinical Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy NSRX?
Nasus Pharma provided a business update highlighting recent Phase 2 results for NS002, its intranasal powder epinephrine product candidate for anaphylaxis. The company reported topline results demonstrating statistically significant improvements in time to therapeutic threshold compared to EpiPen. Nasus is advancing NS002 toward a pivotal clinical study expected to initiate in the Q4 of 2026. "Following the compelling topline Phase 2 results of NS002, we are advancing our intranasal epinephrine powder formulation towards a pivotal study planned to initiate in the fourth quarter of this year," said Dan Teleman, CEO of Nasus Pharma.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NSRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NSRX
Wall Street analysts forecast NSRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.550
Low
19.00
Averages
19.00
High
19.00
Current: 2.550
Low
19.00
Averages
19.00
High
19.00
About NSRX
Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nasus Pharma Ltd. Financial Update Highlights Key Metrics
- Cash Position: As of December 31, 2025, Nasus Pharma reported cash, cash equivalents, and marketable securities totaling $4.3 million, a significant increase from $0.3 million as of December 31, 2024, indicating improved financial management.
- Increased Net Loss: The net loss for the fiscal year 2025 was $5.9 million, compared to a net loss of $1.5 million in 2024, highlighting pressures from operational costs and research expenditures.
- Financing Activity: Following a $15 million private placement completed in February 2026, Nasus expects this funding to sustain its operations through the second quarter of 2027, enhancing market confidence in its financial stability.
- Future Outlook: With successful financing, Nasus Pharma is positioned for greater operational flexibility and growth potential in the future, although the current loss situation remains a concern, the ample funding will support its strategic development.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Nasus Pharma to Host Conference Call on NS002 Clinical Study Results
- Clinical Study Update: Nasus Pharma will host a conference call on March 16, 2026, to discuss the topline analysis from its Phase 2 repeated dose clinical study of NS002, which is expected to provide critical data support for the company's future product development.
- Product Innovation: NS002 is a needle-free intranasal epinephrine powder product designed to offer a more convenient medication option for patients experiencing anaphylaxis, aligning with the need for rapid drug delivery and potentially transforming emergency medication usage.
- Technological Advantage: Nasus' proprietary powder-based intranasal (PBI) technology leverages the nasal cavity's rich vascular network for rapid absorption, which is anticipated to provide faster drug absorption compared to liquid nasal products, enhancing the patient experience.
- Investor Relations: A recording of the webcast will be available on Nasus Pharma's investor relations website following the conference, further enhancing communication and transparency between the company and its investors.
See More
Nasus Pharma to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Nasus Pharma will participate in three investor conferences on February 25, March 2, and March 11, 2026, with CEO Dan Teleman presenting the company, aiming to enhance visibility and attract potential investments.
- Format and Locations: The Oppenheimer conference will be held virtually, while the BIO Investment & Growth Summit and Citizens Life Sciences Conference will take place in Miami, showcasing the company's flexibility in engaging with investors across different platforms.
- Product Development Progress: Nasus Pharma is developing a needle-free intranasal epinephrine powder product, NS002, designed to provide rapid and convenient drug delivery for patients experiencing anaphylaxis, aligning with urgent medical needs and improving patient experience.
- Technological Advantages: The company's proprietary powder-based intranasal (PBI) technology leverages the nasal cavity's rich vascular network for rapid absorption, expected to offer faster drug delivery compared to liquid nasal products, enhancing its competitive edge in the market.
See More
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
See More
Nasus Pharma Ltd. Financial Update Highlights Key Metrics
- Cash Position: As of December 31, 2025, Nasus Pharma reported cash, cash equivalents, and marketable securities totaling $4.3 million, a significant increase from $0.3 million as of December 31, 2024, indicating improved financial management.
- Increased Net Loss: The net loss for the fiscal year 2025 was $5.9 million, compared to a net loss of $1.5 million in 2024, highlighting pressures from operational costs and research expenditures.
- Financing Activity: Following a $15 million private placement completed in February 2026, Nasus expects this funding to sustain its operations through the second quarter of 2027, enhancing market confidence in its financial stability.
- Future Outlook: With successful financing, Nasus Pharma is positioned for greater operational flexibility and growth potential in the future, although the current loss situation remains a concern, the ample funding will support its strategic development.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Nasus Pharma to Host Conference Call on NS002 Clinical Study Results
- Clinical Study Update: Nasus Pharma will host a conference call on March 16, 2026, to discuss the topline analysis from its Phase 2 repeated dose clinical study of NS002, which is expected to provide critical data support for the company's future product development.
- Product Innovation: NS002 is a needle-free intranasal epinephrine powder product designed to offer a more convenient medication option for patients experiencing anaphylaxis, aligning with the need for rapid drug delivery and potentially transforming emergency medication usage.
- Technological Advantage: Nasus' proprietary powder-based intranasal (PBI) technology leverages the nasal cavity's rich vascular network for rapid absorption, which is anticipated to provide faster drug absorption compared to liquid nasal products, enhancing the patient experience.
- Investor Relations: A recording of the webcast will be available on Nasus Pharma's investor relations website following the conference, further enhancing communication and transparency between the company and its investors.
See More
Nasus Pharma to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Nasus Pharma will participate in three investor conferences on February 25, March 2, and March 11, 2026, with CEO Dan Teleman presenting the company, aiming to enhance visibility and attract potential investments.
- Format and Locations: The Oppenheimer conference will be held virtually, while the BIO Investment & Growth Summit and Citizens Life Sciences Conference will take place in Miami, showcasing the company's flexibility in engaging with investors across different platforms.
- Product Development Progress: Nasus Pharma is developing a needle-free intranasal epinephrine powder product, NS002, designed to provide rapid and convenient drug delivery for patients experiencing anaphylaxis, aligning with urgent medical needs and improving patient experience.
- Technological Advantages: The company's proprietary powder-based intranasal (PBI) technology leverages the nasal cavity's rich vascular network for rapid absorption, expected to offer faster drug delivery compared to liquid nasal products, enhancing its competitive edge in the market.
See More
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
See More
